110402-26-1

Basic information

• Product Name: 3-Pyridinethiol,2-aMino-5-chloro-
• Synonyms: 3-Pyridinethiol,2-aMino-5-chloro-
• CAS NO: 110402-26-1
• Molecular Formula: C5H5ClN2S
• Molecular Weight: 160.6246
• Mol File: 110402-26-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 286.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.466±0.06 g/cm3(Predicted)
• PKA: 2.50±0.50(Predicted)
• CAS DataBase Reference: 3-Pyridinethiol,2-aMino-5-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinethiol,2-aMino-5-chloro-(110402-26-1)
• EPA Substance Registry System: 3-Pyridinethiol,2-aMino-5-chloro-(110402-26-1)

Safety Data

• Hazardous Substances Data: 110402-26-1(Hazardous Substances Data)

Relevant articles and documents

CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS

This invention provides compounds defined by Formula I Z-L-R1-Q-D-(V1)m-R2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R1, Q, D, V1, m, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.